These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 16635538

  • 1. Immunotherapy against visceral leishmaniasis with the nucleoside hydrolase-DNA vaccine of Leishmania donovani.
    Gamboa-León R, Paraguai de Souza E, Borja-Cabrera GP, Santos FN, Myashiro LM, Pinheiro RO, Dumonteil E, Palatnik-de-Sousa CB.
    Vaccine; 2006 May 29; 24(22):4863-73. PubMed ID: 16635538
    [Abstract] [Full Text] [Related]

  • 2. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
    Melby PC, Yang J, Zhao W, Perez LE, Cheng J.
    Infect Immun; 2001 Aug 29; 69(8):4719-25. PubMed ID: 11447143
    [Abstract] [Full Text] [Related]

  • 3. Acylated and deacylated saponins of Quillaja saponaria mixture as adjuvants for the FML-vaccine against visceral leishmaniasis.
    Oliveira-Freitas E, Casas CP, Borja-Cabrera GP, Santos FN, Nico D, Souza LO, Tinoco LW, da Silva BP, Palatnik M, Parente JP, Palatnik-de-Sousa CB.
    Vaccine; 2006 May 01; 24(18):3909-20. PubMed ID: 16556475
    [Abstract] [Full Text] [Related]

  • 4. Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis.
    Aguilar-Be I, da Silva Zardo R, Paraguai de Souza E, Borja-Cabrera GP, Rosado-Vallado M, Mut-Martin M, García-Miss Mdel R, Palatnik de Sousa CB, Dumonteil E.
    Infect Immun; 2005 Feb 01; 73(2):812-9. PubMed ID: 15664920
    [Abstract] [Full Text] [Related]

  • 5. Immunogenicity of a multicomponent DNA vaccine against visceral leishmaniasis in dogs.
    Saldarriaga OA, Travi BL, Park W, Perez LE, Melby PC.
    Vaccine; 2006 Mar 10; 24(11):1928-40. PubMed ID: 16310897
    [Abstract] [Full Text] [Related]

  • 6. A heterologous prime-boost vaccination regimen using ORFF DNA and recombinant ORFF protein confers protective immunity against experimental visceral leishmaniasis.
    Tewary P, Jain M, Sahani MH, Saxena S, Madhubala R.
    J Infect Dis; 2005 Jun 15; 191(12):2130-7. PubMed ID: 15898000
    [Abstract] [Full Text] [Related]

  • 7. Vaccination with recombinant Leishmania donovani gamma-glutamylcysteine synthetase fusion protein protects against L. donovani infection.
    Henriquez FL, Campbell SA, Roberts CW, Mullen AB, Burchmore R, Carter KC.
    J Parasitol; 2010 Oct 15; 96(5):929-36. PubMed ID: 20950100
    [Abstract] [Full Text] [Related]

  • 8. Leishmanial antigens in liposomes promote protective immunity and provide immunotherapy against visceral leishmaniasis via polarized Th1 response.
    Bhowmick S, Ravindran R, Ali N.
    Vaccine; 2007 Aug 29; 25(35):6544-56. PubMed ID: 17655984
    [Abstract] [Full Text] [Related]

  • 9. Aluminium phosphate potentiates the efficacy of DNA vaccines against Leishmania mexicana.
    Rosado-Vallado M, Mut-Martin M, García-Miss Mdel R, Dumonteil E.
    Vaccine; 2005 Nov 16; 23(46-47):5372-9. PubMed ID: 16054271
    [Abstract] [Full Text] [Related]

  • 10. DNA vaccination against the parasite enzyme gamma-glutamylcysteine synthetase confers protection against Leishmania donovani infection.
    Carter KC, Henriquez FL, Campbell SA, Roberts CW, Nok A, Mullen AB, McFarlane E.
    Vaccine; 2007 May 30; 25(22):4502-9. PubMed ID: 17418459
    [Abstract] [Full Text] [Related]

  • 11. Co-administration of IL-12 DNA with rORFF antigen confers long-term protective immunity against experimental visceral leishmaniaisis.
    Tewary P, Saxena S, Madhubala R.
    Vaccine; 2006 Mar 20; 24(13):2409-16. PubMed ID: 16413950
    [Abstract] [Full Text] [Related]

  • 12. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
    Lemesre JL, Holzmuller P, Gonçalves RB, Bourdoiseau G, Hugnet C, Cavaleyra M, Papierok G.
    Vaccine; 2007 May 22; 25(21):4223-34. PubMed ID: 17395339
    [Abstract] [Full Text] [Related]

  • 13. Leishmania donovani recombinant iron superoxide dismutase B1 protein in the presence of TLR-based adjuvants induces partial protection of BALB/c mice against Leishmania major infection.
    Daifalla NS, Bayih AG, Gedamu L.
    Exp Parasitol; 2012 Jul 22; 131(3):317-24. PubMed ID: 22580023
    [Abstract] [Full Text] [Related]

  • 14. Enhanced efficacy and immunogenicity of 78kDa antigen formulated in various adjuvants against murine visceral leishmaniasis.
    Nagill R, Kaur S.
    Vaccine; 2010 May 21; 28(23):4002-12. PubMed ID: 20093205
    [Abstract] [Full Text] [Related]

  • 15. Serodiagnostic and immunoprophylactic potential of a 78kDa protein of Leishmania donovani of Indian origin.
    Mukherjee M, Bhattacharyya A, Duttagupta S.
    Med Sci Monit; 2002 Apr 21; 8(4):BR117-22. PubMed ID: 11951057
    [Abstract] [Full Text] [Related]

  • 16. Comparison of liposome based antigen delivery systems for protection against Leishmania donovani.
    Bhowmick S, Mazumdar T, Sinha R, Ali N.
    J Control Release; 2010 Jan 25; 141(2):199-207. PubMed ID: 19818373
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of immune responses and protection induced by A2 and nucleoside hydrolase (NH) DNA vaccines against Leishmania chagasi and Leishmania amazonensis experimental infections.
    Zanin FH, Coelho EA, Tavares CA, Marques-da-Silva EA, Silva Costa MM, Rezende SA, Gazzinelli RT, Fernandes AP.
    Microbes Infect; 2007 Jul 25; 9(9):1070-7. PubMed ID: 17644455
    [Abstract] [Full Text] [Related]

  • 18. Leishmania infantum: prime boost vaccination with C-terminal extension of cysteine proteinase type I displays both type 1 and 2 immune signatures in BALB/c mice.
    Rafati S, Zahedifard F, Azari MK, Taslimi Y, Taheri T.
    Exp Parasitol; 2008 Mar 25; 118(3):393-401. PubMed ID: 18093586
    [Abstract] [Full Text] [Related]

  • 19. Comparison of potential protection induced by three vaccination strategies (DNA/DNA, Protein/Protein and DNA/Protein) against Leishmania major infection using Signal Peptidase type I in BALB/c mice.
    Rafati S, Ghaemimanesh F, Zahedifard F.
    Vaccine; 2006 Apr 12; 24(16):3290-7. PubMed ID: 16481076
    [Abstract] [Full Text] [Related]

  • 20. A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice.
    Mazumdar T, Anam K, Ali N.
    Vaccine; 2004 Mar 12; 22(9-10):1162-71. PubMed ID: 15003644
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.